Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
821-840 of 2,251 trials

Stroke Treatment Study: Tirofiban vs. Aspirin

We are comparing the effectiveness and safety of tirofiban and aspirin for patients with acute ischemic stroke caused by tandem lesions. This study aims to find out which treatment better prevents complications and improves recovery.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNeurology

Hyperkalaemia in Children: SZC Treatment Study

We are studying whether the medication SZC can safely normalize potassium levels in children with hyperkalaemia. The trial will also check how well it maintains these levels over time.

High Potassium Levels (Hyperkalemia)6-12 monthsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNephrologyPediatrics

Crohn's Disease: New Ultrasound Method with Microbubbles

We are testing a novel ultrasound technique using oral contrast to improve the detection of Crohn's disease complications. This study aims to see if it can identify issues like ulcers and blockages in the small intestine.

Crohn's Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Chronic Kidney Disease: Camostat Treatment

We are studying the effects of Camostat on kidney function in patients with chronic kidney disease. The goal is to see if it helps with salt and water balance and blood pressure compared to healthy individuals.

Chronic Kidney Disease with Proteinuria1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNephrology

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Coronary Artery Disease: Comparing Diabetes Medications

We are studying how well a new diabetes medication works to improve heart health in people with coronary artery disease and prediabetes. This trial compares a GLP-1 agonist and an SGLT-2 inhibitor to standard treatment.

Coronary Artery DiseasePrediabetesCoronary Atherosclerosis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyEndocrinology

Mechanical Heart Valves: Lower INR Study

We are evaluating if a lower INR range is safer and more effective for patients with bileaflet aortic mechanical valves. This may help reduce bleeding risks associated with current treatment methods.

Aortic Valve Replacement Treatment>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Neuroendocrine Tumors: Personalized vs. Standard RadioTherapy

We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.

Neuroendocrine Tumors6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Kidney Health in Type 2 Diabetes: Empagliflozin and Finerenone Study

We are exploring how well two medications work for kidney health in people with type 2 diabetes. This remote trial aims to personalize treatment based on individual responses.

Type 2 DiabetesAlbuminuria≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteDiabetologyInternal MedicineNephrology

Multiple Myeloma: Treatment-Free Interval Study

We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.

Multiple Myeloma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

High-Risk Neuroblastoma: Naxitamab and GM-CSF Treatment

We are studying a new treatment combining naxitamab and GM-CSF for children with high-risk neuroblastoma who have not responded to prior therapies. The trial aims to assess how well this treatment works and its safety.

Recurrent Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Multiple Myeloma: AZD0305 Treatment Study

We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Metastatic Breast Cancer: FDG-PET/CT vs. Conventional CT

We are studying whether FDG-PET/CT can better monitor treatment response in metastatic breast cancer patients compared to conventional CT. This may help improve survival and quality of life for those involved.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Advanced Melanoma: Vusolimogene Oderparepvec with Nivolumab

We are comparing a new treatment combination for advanced melanoma that has worsened after other therapies. The goal is to see if this combination improves survival and response compared to standard treatment options.

Advanced MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Graft-Versus-Host Disease: Corticosteroids with ECP

We are studying whether adding extracorporeal photopheresis to corticosteroids helps patients with Grade II acute graft-versus-host disease after stem cell transplantation. This trial compares treatment outcomes and side effects between the two approaches.

Acute Graft-Versus-Host Disease (GVHD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

BRAF V600E Mutated Metastatic Colorectal Cancer: ENCORAFENIB and FOLFIRI

We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.

Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HIV Treatment Comparison: Doravirine vs. Dolutegravir

We are studying whether doravirine is as effective as dolutegravir for people newly diagnosed with HIV-1. The trial also examines potential side effects and health changes over time.

HIV Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

HIV and HBV Co-Infection: Antiviral Treatment Strategies

We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.

Co-infection with HIV-1 and HBV>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHepatologyInfectious Diseases

Patellofemoral Osteoarthritis: Nasal Cartilage Implant Study

We are investigating whether a new treatment using engineered nasal cartilage can help reduce pain and improve knee function in people with osteoarthritis behind the kneecap. This study compares the new approach to standard treatments.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology